UY25951A1 - PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II) - Google Patents

PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II)

Info

Publication number
UY25951A1
UY25951A1 UY25951A UY25951A UY25951A1 UY 25951 A1 UY25951 A1 UY 25951A1 UY 25951 A UY25951 A UY 25951A UY 25951 A UY25951 A UY 25951A UY 25951 A1 UY25951 A1 UY 25951A1
Authority
UY
Uruguay
Prior art keywords
protein
seq
amino acids
amino acid
acid sequence
Prior art date
Application number
UY25951A
Other languages
Spanish (es)
Inventor
Patricia Beckmann
Raymond Goodwin
Craig Smith
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to UY25951A priority Critical patent/UY25951A1/en
Publication of UY25951A1 publication Critical patent/UY25951A1/en

Links

Abstract

Una composición que consiste esencialmente en una proteína que comprende una secuencia de aminoácidos seleccionados del grupo de aminoácidos 1- 163 de SEQ ID NO:2 y los aminoácidos 1-233 de SEQ ID NO:4, en donde dicha proteína puede unirse a TNF. Una composición farmacéutica que incluya una proteina, y un diluyente o vehiculo aceptables desde el punto de vista farmacéutico. Una proteina libre de proteinas no especificas que comprende una secuencia de aminoacidos seleccionados del grupo que consiste en los aminácidos 1-163 de SEQ ID NO:2 y los aminoacidos 1-233 de SEQ ID NO:4, donde dicha proteina puede unirse a TNF. Una proteina aislada y purificada que comprende un polipéptido identico a un polipéptido que tiene una secuencia de aminoacidos que comprende los aminoacidos 1-163 de SEQ ID NO:2, o idéntica a un polipéptido que tiene una secuencia de aminoácidos que comprende los aminoacidos 1-233 de SEQ ID NO:4, con la excepción de una o más modificaciones de la secuencia de aminoácidos selecionados del grupo que consiste en: 1- inactivación de sitios de glicosilación de enlace N; 2- modificación de puntos de ruptura de proteasa KEX2; y 3- sustituición o supresión de residuos de cisteina, donde dicha protiena puede unirse puede a TNF.A composition consisting essentially of a protein comprising an amino acid sequence selected from amino acid group 1- 163 of SEQ ID NO: 2 and amino acids 1-233 of SEQ ID NO: 4, wherein said protein can bind TNF. A pharmaceutical composition including a protein, and a pharmaceutically acceptable diluent or carrier. A protein free of non-specific proteins comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO: 2 and amino acids 1-233 of SEQ ID NO: 4, where said protein can bind TNF . An isolated and purified protein comprising a polypeptide identical to a polypeptide having an amino acid sequence comprising amino acids 1-163 of SEQ ID NO: 2, or identical to a polypeptide having an amino acid sequence comprising amino acids 1- 233 of SEQ ID NO: 4, with the exception of one or more amino acid sequence modifications selected from the group consisting of: 1- inactivation of N-link glycosylation sites; 2- modification of KEX2 protease breakpoints; and 3- substitution or deletion of cysteine residues, where said protein can bind to TNF.

UY25951A 2000-01-17 2000-01-17 PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II) UY25951A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY25951A UY25951A1 (en) 2000-01-17 2000-01-17 PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY25951A UY25951A1 (en) 2000-01-17 2000-01-17 PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II)

Publications (1)

Publication Number Publication Date
UY25951A1 true UY25951A1 (en) 2001-08-27

Family

ID=38812147

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25951A UY25951A1 (en) 2000-01-17 2000-01-17 PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II)

Country Status (1)

Country Link
UY (1) UY25951A1 (en)

Similar Documents

Publication Publication Date Title
Carlsen et al. Human chorionic gonadotropin: linear amino acid sequence of the β subunit
PL372849A1 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
KR850004273A (en) Recombinant gamma interferon with increased stability and preparation method thereof
ECSP064643A (en) GLP-1 FUSION PROTEINS
AR065349A1 (en) GLUCAGON / GLP-1 RECEIVER COAGONISTS
EE05111B1 (en) Interferon beta-fusion proteins and their use
CY1105616T1 (en) PEPTIDE INHIBITORS OF TGFβ1
AR062867A2 (en) INTERLEUQUINE LINK PROTEINS -18, (IL-18BP), DNA SEQUENCES CODING FOR IL -18 BP, cDNA SEQUENCES, A REPLICABLE EXPRESSION VEHICLE, GUEST CELL, A PROCESS FOR PRODUCTION AND INSULATION, ANTIBODIES, COMPOUNDS, COMPOUNDS PHARMACEUTICS, THE USE OF SUCH COMPOSITIONS FOR THE
BR9913698A (en) Enterotoxin signaling peptide ii from e. modified coli and a microorganism expressing a peptide fusion protein and a heterologous protein
ATE278708T1 (en) CONOTOXIN PEPTIDE PVIIA
KR880009125A (en) Pancreatic secretive trypsin inhibitors and variants thereof, methods thereof, expression vectors and recombinant hosts and pharmaceutical uses thereof produced by recombinant hosts
BR9306272A (en) Peptide and pharmaceutical composition
RU93045577A (en) MULTIPLE POLYPEPTIDES
RS49517B (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
DE69827262D1 (en) PENAEIDINE: ANTIMICROBIAL PEPTIDES FROM CARBURATORS
FI893833A0 (en) REKOMBINANT AKTIVATOR FOER NATURLIGA DOEDARCELLER.
UY25951A1 (en) PURIFIED TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES (TYPE II)
ATE294816T1 (en) NEW, PHYSIOLOGICALLY ACTIVE PEPTIDES AND THEIR USE.
ATE291033T1 (en) THERAPEUTIC PEPTIDES
AR026068A1 (en) MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY.
ATE25984T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES.
DK0946591T3 (en) Cloned glucagon-like peptide-2 receptors
DE69928947D1 (en) MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF
ES2063519T3 (en) SYNTHETIC PEPTIDES THAT ANTAGONIZE NEUROQUININE A, ITS SALTS AND ITS PREPARATION PROCEDURES.
ATE46173T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20110505